Low-dose compared to manufacturer-recommended dose four-factor prothrombin complex concentrate for acute warfarin reversal.

Wesley R ZemrakFrancis ManuelKathryn E SmithStephen RolfeTimothy HayesRobert L TrowbridgeBrian CarloneDavid Seder

Published in: Journal of thrombosis and thrombolysis (2019)

Utilization of a low-dose 4F-PCC strategy resulted in fewer patients achieving target INR reversal, but no difference in hemostatic efficacy, thromboembolic events, or survival.

Keyphrases

low dose
end stage renal disease
high dose
atrial fibrillation
ejection fraction
newly diagnosed
chronic kidney disease
liver failure
venous thromboembolism
peritoneal dialysis
patient reported outcomes
intensive care unit
drug induced
patient reported
oral anticoagulants